Maryland is currently home to 2746 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
NCT05048875
Recruiting
The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection. This study is hypothesizing that the highest dose of the investigational study drug is superior to receiving a placebo with respect to its antiviral activity in healthy adult participants inoculated with Dengue Serotype 3.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/09/2023
Locations: Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland
Conditions: Dengue
Register for Updates
Wearable tES for Insomnia
NCT06100185
Recruiting
The purpose of this study is to investigate the ability of a translational device, Teledyne PeakSleep, to reduce sleep onset latency, reduce time awake after sleep onset and improve restfulness and the subjective benefits of sleep in a patient population with insomnia via transcranial direct current stimulation (tDCS) applied to frontal lobe circuits.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
11/02/2023
Locations: Walter Reed National Military Medical Center, Bethesda, Maryland
Conditions: Insomnia
Register for Updates
Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease
NCT03808103
Recruiting
This study will evaluate the safety of oral administration of EcoActive to patients with inactive Crohn's disease and how it affects the levels of AIEC in stool.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/02/2023
Locations: Johns Hopkins Green Spring Station, Lutherville, Maryland
Conditions: Crohn Disease
Register for Updates
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
NCT03110822
Recruiting
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/30/2023
Locations: Regional Cancer Care Associates (RCCA) MD, LLC, Bethesda, Maryland
Conditions: Multiple Myeloma
Register for Updates
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
NCT05082519
Recruiting
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy... Read More
Gender:
All
Ages:
Between 10 years and 25 years
Trial Updated:
10/25/2023
Locations: Johns Hopkins / Sydney Kimmel Cancer Center, Baltimore, Maryland
Conditions: B-cell Acute Lymphoblastic Leukemia, Obesity
Register for Updates
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646
Recruiting
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an... Read More
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
10/24/2023
Locations: ACTION3 Investigational Site 8, Baltimore, Maryland
Conditions: FSGS
Register for Updates
Developing a Nationwide Registry to Track Longitudinal Clinical Outcomes of Corneal Surgery and Disease
NCT06101017
Recruiting
The goal is to develop a nationwide registry to track longitudinal clinical outcomes of and store imaging data related to numerous corneal conditions. There are two main objectives including the establishment of the first nationwide corneal transplant registry in the United States to include information related to the donor tissue, recipient, surgical procedure, and long-term clinical outcomes. Ultimately, this prospective data collection will allow us to determine prognostic factors for success... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: Keratoplasty Alliance International, Baltimore, Maryland
Conditions: Corneal Disease, Endothelial Corneal Dystrophy, Corneal Transplant Failure, Corneal Transplant Rejection
Register for Updates
Intervention for Sexual and Biomedical HIV Prevention in Vulnerable U.S. Young Adults
NCT06096324
Recruiting
The study team will conduct a two-group study to examine the efficacy of implementing an enhanced microenterprise intervention to improve economic stability and HIV preventive behaviors. The team will enroll approximately 780 young adults. Participants will be randomly assigned to one of two groups. The first group ("control") will receive text messages with information on job openings. The second group ("intervention") will receive text messages with information on job openings plus HIV prevent... Read More
Gender:
All
Ages:
Between 18 years and 24 years
Trial Updated:
10/19/2023
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Economic Hardship, Condomless Sex, Utilization, Health Care
Register for Updates
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971
Recruiting
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
10/17/2023
Locations: MD Medical Research, Oxon Hill, Maryland
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Register for Updates
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT05283330
Recruiting
A Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of ²¹²Pb-DOTAM-GRPR1 in subjects with various GRPR-expressing Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Advanced Molecular Imaging and Therapy, Glen Burnie, Maryland
Conditions: Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma
Register for Updates
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
NCT04858776
Recruiting
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for at least 14 days and no more than 60 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and imp... Read More
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
10/17/2023
Locations: Medstar Health Research Institute, Hyattsville, Maryland
Conditions: Iliofemoral; Thrombosis
Register for Updates
Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)
NCT05123222
Recruiting
This study will include 4 cohorts of 14 ZIKV and DENV-naïve female and male subjects, 18 - 40 years of age (total: up to 56 subjects). Within each cohort, 10 subjects will receive ZIKV and 4 subjects will receive a placebo on Study Day 0. Cohorts 1 and 2 (Dose = 10^2 PFU) will be enrolled first and will enroll only women. Cohorts 3 and 4 (Dose = 10^2 PFU) will enroll men.
Gender:
All
Ages:
Between 18 years and 40 years
Trial Updated:
10/12/2023
Locations: Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland
Conditions: Zika Virus
Register for Updates